Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche span> par promoteur : Pfizer Limited
Femme et Homme Max 99 ans
Pfizer Limited
MAJ Il y a 5 ans
A CLUSTER RANDOMIZED TRIAL ON CARDIOVASCULAR RISK FACTOR MANAGEMENT: CADUET® VERSUS USUAL CARE IN SUBJECTS WITH HYPERTENSION AND ADDITIONAL CARDIOVASCULAR RISK FACTORS IN CLINICAL PRACTICE
To investigate whether a Caduet®-based multi-factorial risk factor management strategy might result in greater reduction in total cardiovascular risk as compared with a usual care strategy after one y...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Limited, Ramsgate Road, Sandwich, Kent, UK
MAJ Il y a 5 ans
A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF MONOTHERAPY SITAXSENTAN SODIUM VERSUS COMBINATION THERAPY WITH SITAXSENTAN SODIUM AND SILDENAFIL CITRATE IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION WHO HAVE COMPLETED STUDY B1321001
The primary objective of this study is to evaluate the efficacy of sitaxsentan (100 mg once daily) plus sildenafil (20 mg TID) as compared to sitaxsentan monotherapy by determining time to clinical wo...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Pfizer Limited
MAJ Il y a 5 ans
A MULTI-CENTER, RANDOMIZED, CROSS-OVER, DOUBLE-BLIND, THIRD PARTY OPEN, PLACEBO CONTROLLED, PILOT STUDY TO ASSESS THE URODYNAMIC EFFECTS OF MODIFIED RELEASE UK-369,003 IN MEN WITH LOWER URINARY TRACT SYMPTOMS (LUTS)
• A pilot study to assess the urodynamic changes induced by 100mg MR formulation of UK-369,003 vs. placebo in men with LUTS. • Assess the safety and tolerability of UK-369,003 in men with LUTS
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Limited
MAJ Il y a 5 ans
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF A NOVEL CCR5 ANTAGONIST, UK-427,857, IN COMBINATION WITH OPTIMIZED BACKGROUND THERAPY VERSUS OPTIMIZED BACKGROUND THERAPY ALONE FOR THE TREATMENT OF ANTIRETROVIRAL EXPERIENCED, NON CCR5-TROPIC HIV-1 INFECTED SUBJECTS
To confirm that the hypothesis that UK-427,857 added to Optimised Background Therapy (OBT) provides an additional reduction in plasma HIV-1 RNA compared to OBT alone, as measured by the difference bet...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Limited, Ramsgate Road, Sandwich, Kent
MAJ Il y a 5 ans
A 6 MONTH, PROSPECTIVE, OPEN-LABEL MULTIPLE CENTER EXTENSION TRIAL TO EVALUATE THE LONG TERM SAFETY AND SUSTAINED EFFICACY OF FRAGMIN IN THE TREATMENT OF CHRONIC FOOT ULCERS IN DIABETIC PATIENTS WITH PERIPHERAL ARTERIAL OCCLUSIVE DISEASE
The primary objective of this 6 month open-label extension trial is to evaluate long-term safety and tolerability of dalteparin in treatment of chronic neuroischaemic foot ulcers in diabetic patients ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Limited
MAJ Il y a 5 ans
A Double Blind Parallel Group Randomised Multiple Dose Study to Evaluate the pharmacodynamic response and safety of Pha-794428 in adult growth hormone deficient Patients
Main objectives: To explore the safety, toleration and humoral response of PHA-794428 after multiple weekly injections in AGHD patients. To explore the dose response relationship of PHA-794428 af...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Pfizer Limited
MAJ Il y a 5 ans
A Phase 2 multi-center, open label, long-term extension trial to assess the safety of oral UK-390,957 administered as required in adult men with premature ejaculation
To evaluate the long-term safety and tolerability of oral UK-390,957 administered to adult men with premature ejaculation who have successfully completed 1 of the Pfizer trials A3871022, A3871027 or A...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Limited, Ramsgate Road, Sandwich, Kent, UK
MAJ Il y a 5 ans
Oral Revatio in Pediatric PAH - Long-term follow-on Study to A1481131
The primary objective is to assess the safety and tolerability of oral sildenafil in the chronic treatment of pediatric subjects with PAH.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Limited, Ramsgate Road,Sandwich,Kent CT13 9NJ
MAJ Il y a 5 ans
A PHASE 2A RANDOMIZED, DOUBLE-BLINDED, DOUBLE DUMMY, PLACEBO AND ACTIVE CONTROLLED, TWO-WAY CROSS-OVER, FLARE-ENRICHED MULTI-CENTRE CLINICAL TRIAL TO EXAMINE THE PAIN RELIEF PRODUCED BY 2 WEEKS OF DAILY ORAL ADMINISTRATION OF A FATTY ACID AMIDE HYDROLASE (FAAH) INHIBITOR PF-04457845 IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE
•To evaluate the efficacy of PF-04457845 (administered QD) versus placebo in relieving pain in patients with osteoarthritis of the knee. •To evaluate the safety and tolerability of PF-04457845 in pati...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Limited
MAJ Il y a 5 ans
LINEZOLID IN THE TREATMENT OF SUBJECTS WITH COMPLICATED SKIN AND SOFT TISSUE INFECTIONS PROVEN TO BE DUE TO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS
To compare the clinical efficacy of linezolid to vancomycin in the treatment of complicated skin and soft tissue infections (cSSTI) due to MRSA in adult subjects at the End of Study (EOS) visit.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
Suivant